Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
General Primary Care
•
General Psychiatry
Do you recommend tapering patients with long-term benzodiazepine use for anxiety who are stable and functional, and assuming no side effects or concerns for misuse?
Related Questions
How long do you generally continue anti-depressants for mild-to-moderate depression who have achieved remission?
In an older adults with dementia-related behavioral symptoms refractory to nonpharmacological management in whom you are starting SSRI, do you ever consider a short course of antipsychotic medication to overlap with the initiation of SSRI while waiting for therapeutic effect?
How do you balance the risks and benefits of stimulant treatment in patients with poorly controlled hypertension?
What additional workup would you perform to evaluate a new onset of spontaneous hemarthrosis?
What class(es) of antihypertensives should be considered next for refractory hypertension in a patient compliant with high doses of Entresto, chlorthalidone, amlodipine, clonidine, and spironolactone if they previously did not have any improvement on beta blocker or hydralazine and work-up for secondary causes were unremarkable?
What would be your next diagnostic test of choice for a patient with findings concerning for silent ischemia on noninvasive functional testing in the absence of chest pain?
What patient factors influence your recommendation of daily or every other day iron for the treatment of iron deficiency anemia?
How do you address social determinants of health that impact patients (e.g., housing instability, food insecurity) but for which there are no immediate resources available?
What is your risk/benefit analysis when deciding on the appropriateness and timing for discontinuation of systemic anticoagulation in patients who underwent ablation for paroxysmal atrial fibrillation with CHADS2VASc score >2?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
